(Q36300100)

13 August 2017

1 reference

title

Silymarin treatment of viral hepatitis: a systematic review (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Mayer KE

1

1 reference

13 August 2017

Myers RP

series ordinal

2

1 reference

13 August 2017

Lee SS

series ordinal

3

1 reference

13 August 2017

publication date

1 November 2005

1 reference

Journal of Viral Hepatitis

13 August 2017

published in

1 reference

13 August 2017

volume

12

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

559-567

1 reference

Management of chronic hepatitis B.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Hepatitis B virus: old, new and future approaches to antiviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Milk thistle for the treatment of liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Flavonoid antioxidant silymarin and skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Oxidative stress in chronic hepatitis C: not just a feature of late stage disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Hepatic stellate cells: a target for the treatment of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Silymarin Retards the Progression of Alcohol-Induced Hepatic Fibrosis in Baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Complementary and alternative medicine in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Long-term follow-up study of sustained biochemical responders with interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Clinical studies with silymarin: fibrosis progression is the end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00636.X

Evaluation of the silymarin content inSilybum marianum (L.) Gaertn. Cultivated under different agricultural conditions

21 January 2018

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1002/PTR.2650070122

10.1111/J.1365-2893.2005.00636.X

10 April 2024

Identifiers

DOI

1 reference

release_m3r43sxeynalnfouhowevmifcm

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m3r43sxeynalnfouhowevmifcm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference